Merck Manual

Please confirm that you are a health care professional

Loading

Antithrombin Deficiency

By

Joel L. Moake

, MD, Baylor College of Medicine

Last full review/revision Aug 2019| Content last modified Aug 2019
Click here for Patient Education
Topic Resources

Because antithrombin inhibits thrombin and factors Xa, IXa, and XIa, deficiency of antithrombin predisposes to venous thrombosis.

Antithrombin is a plasma protein that inhibits thrombin and factors Xa, IXa, and XIa, thereby inhibiting thrombosis.

Heterozygous deficiency of antithrombin has a prevalence of about 0.2 to 0.4%; about half of people affected develop venous thromboses. Homozygous deficiency is probably lethal to the fetus in utero.

Acquired deficiencies occur in patients with disseminated intravascular coagulation, liver disease, or nephrotic syndrome, or during heparin therapy. Heparin exerts its anticoagulant effect by activating antithrombin.

Laboratory testing is done for patients with an unexplained blood clot and involves quantification of the capacity of patient plasma to inhibit thrombin in the presence of heparin.

Treatment

  • Warfarin to prevent venous thromboembolism

Oral warfarin is used for prophylaxis against venous thromboembolism.

It is probable, but not yet certain, that the direct oral anticoagulant (DOAC) inhibitors of either thrombin (dabigatran) or factor Xa (eg, rivaroxaban, apixaban, edoxaban) can be used in place of warfarin in this disorder.

Drugs Mentioned In This Article

Drug Name Select Trade
XARELTO
COUMADIN
SAVAYSA
ELIQUIS
PANHEPRIN
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest

Videos

View All
Bone Marrow Biopsy
Video
Bone Marrow Biopsy
Overview of ADP Receptor
Video
Overview of ADP Receptor
ADP receptors are integral proteins embedded in a platelet membrane. When ADP binds, it causes...

SOCIAL MEDIA

iOS Android
iOS Android
iOS Android
TOP